Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology.
Mercuri FA, White S, McQuilten HA, Lemech C, Mynhardt S, Hari R, Zhang P, Kruger N, McLachlan G, Miller BE, West NP, Tal-Singer R, Demaison C.
Mercuri FA, et al. Among authors: miller be.
ERJ Open Res. 2024 Dec 9;10(6):00199-2024. doi: 10.1183/23120541.00199-2024. eCollection 2024 Nov.
ERJ Open Res. 2024.
PMID: 39655168
Free PMC article.